Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of SPA100 (Aliskiren/Amlodipine) in hypertension
NCT01237873Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aliskiren and amlodipine in essential hypertension, sponsored by Novartis. Primary endpoint: Long-term safety of the fixed-dose combination of aliskiren/amlodipine at 52 weeks. Started Jan 2011; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01237873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237873.